Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 11/20 | 0.68 |
| ▸ | GLP1R | P43220 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38661265 | 0.97 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL6510905 | 0.97 | GRPR (0.68) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL30118089 | 0.96 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL31069834 | 0.96 | GRPR (0.66) | GRPRGLP1R | |
| SCHEMBL2193571 | 0.95 | GRPR (0.67) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL31223150 | 0.95 | GRPR (0.61) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL30816315 | 0.95 | GRPR (0.63) | GRPRGLP1R | |
| SCHEMBL30628977 | 0.95 | GRPR (0.64) | GRPRGLP1R | |
| SCHEMBL30628996 | 0.94 | GRPR (0.62) | GRPRGLP1R | |
| SCHEMBL38661925 | 0.94 | GRPR (0.61) | GRPRGLP1ROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098519-A1 | RADIOLIGAND COMPOUNDS AND USES THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2026-05-15 | — | — | WO | disclosed |
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| CN-120081907-A | Radiolabeled bombesin derivative compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2025-06-03 | — | — | CN | disclosed |
| CN-119868594-A | Method for radiolabelling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114728087-B | Method for radiolabelling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20220401593-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220378954-A1 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | NOVARTIS AG (CH) | 2022-12-01 | — | — | US | disclosed |
| EP-4031193-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| EP-4031194-A1 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728087-A | Method for radiolabeling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728088-A | Stable concentrated radiopharmaceutical compositions | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | RAB5IF, TMEM14C, PAICS | GRPR 1170/4885GLP1R 2897/4885OPRM1 1823/4885 |
| US-20220378954-A1 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | GRPR, CCKBR, GIPR | GRPR 1/4885GLP1R 18/4885OPRM1 723/4885 |
| US-20220401593-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | RAB5IF, TMEM14C, PAICS | GRPR 1170/4885GLP1R 2897/4885OPRM1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.